Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bc1bc3b31e16b85155d0a0b714680f147> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bc1bc3b31e16b85155d0a0b714680f147 NCIT_P378 "NCI" @default.
- Bc1bc3b31e16b85155d0a0b714680f147 type Axiom @default.
- Bc1bc3b31e16b85155d0a0b714680f147 annotatedProperty IAO_0000115 @default.
- Bc1bc3b31e16b85155d0a0b714680f147 annotatedSource NCIT_C166686 @default.
- Bc1bc3b31e16b85155d0a0b714680f147 annotatedTarget "An orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B-cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage. SYK, a non-receptor cytoplasmic protein tyrosine kinase widely expressed in hematopoietic cells, plays a key role in Fc receptor and B-cell receptor signaling in inflammatory cells. It is involved in coupling activated immunoreceptors, such as Fc receptors and B-cell receptors, to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis, which are important for allergic and antibody-mediated immune diseases such as immune thrombocytopenia (ITP)." @default.